Key facts
- This page summarizes John K. Clarke's Form 4 filing for aTYR PHARMA INC (ATYR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 May 2024, 19:30.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.